TY - JOUR
T1 - Use of a Commercial 7-T MRI Scanner for Clinical Brain Imaging
T2 - Indications, Protocols, Challenges, and Solutions—A Single-Center Experience
AU - Özütemiz, Can
AU - White, Matthew
AU - Elvendahl, Wendy
AU - Eryaman, Yigitcan
AU - Marjańska, Małgorzata
AU - Metzger, Gregory J.
AU - Patriat, Rémi
AU - Kulesa, Jeramy
AU - Harel, Noam
AU - Watanabe, Yoichi
AU - Grant, Andrea
AU - Genovese, Guglielmo
AU - Cayci, Zuzan
N1 - Publisher Copyright:
© 2023 American Roentgen Ray Society. All rights reserved.
PY - 2023/12
Y1 - 2023/12
N2 - The first commercially available 7-T MRI scanner (Magnetom Terra) was approved by the FDA in 2017 for clinical imaging of the brain and knee. After initial protocol development and sequence optimization efforts in volunteers, the 7-T system, in combination with an FDA-approved 1-channel transmit/32-channel receive array head coil, can now be routinely used for clinical brain MRI examinations. The ultrahigh field strength of 7-T MRI has the advantages of improved spatial resolution, increased SNR, and increased CNR but also introduces an array of new technical challenges. The purpose of this article is to describe an institutional experience with the use of the commercially available 7-T MRI scanner for routine clinical brain imaging. Specific clinical indications for which 7-T MRI may be useful for brain imaging include brain tumor evaluation with possible perfusion imaging and/or spectroscopy, radiotherapy planning; evaluation of multiple sclerosis and other demyelinating diseases, evaluation of Parkinson disease and guidance of deep brain stimulator placement, high-detail intracranial MRA and vessel wall imaging, evaluation of pituitary pathology, and evaluation of epilepsy. Detailed protocols, including sequence parameters, for these various indications are presented, and implementation challenges (including artifacts, safety, and side effects) and potential solutions are explored.
AB - The first commercially available 7-T MRI scanner (Magnetom Terra) was approved by the FDA in 2017 for clinical imaging of the brain and knee. After initial protocol development and sequence optimization efforts in volunteers, the 7-T system, in combination with an FDA-approved 1-channel transmit/32-channel receive array head coil, can now be routinely used for clinical brain MRI examinations. The ultrahigh field strength of 7-T MRI has the advantages of improved spatial resolution, increased SNR, and increased CNR but also introduces an array of new technical challenges. The purpose of this article is to describe an institutional experience with the use of the commercially available 7-T MRI scanner for routine clinical brain imaging. Specific clinical indications for which 7-T MRI may be useful for brain imaging include brain tumor evaluation with possible perfusion imaging and/or spectroscopy, radiotherapy planning; evaluation of multiple sclerosis and other demyelinating diseases, evaluation of Parkinson disease and guidance of deep brain stimulator placement, high-detail intracranial MRA and vessel wall imaging, evaluation of pituitary pathology, and evaluation of epilepsy. Detailed protocols, including sequence parameters, for these various indications are presented, and implementation challenges (including artifacts, safety, and side effects) and potential solutions are explored.
KW - Keywords 7 T
KW - MRI
KW - brain imaging
KW - neuroradiology
UR - http://www.scopus.com/inward/record.url?scp=85178539655&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85178539655&partnerID=8YFLogxK
U2 - 10.2214/AJR.23.29342
DO - 10.2214/AJR.23.29342
M3 - Article
C2 - 37377363
AN - SCOPUS:85178539655
SN - 0361-803X
VL - 221
SP - 788
EP - 805
JO - American Journal of Roentgenology
JF - American Journal of Roentgenology
IS - 6
ER -